References

References:

  1. Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, Rawla P, Barsouk A. Epidemiology of Renal Cell Carcinoma. World J Oncol. 2020 Jun;11(3):79-87. doi: 10.14740/wjon1279. Epub 2020 May 14. PMID: 32494314; PMCID: PMC7239575.
  2. Pathology Outlines. Section on Renal Cell Carcinoma. https://www.pathologyoutlines.com/topic/kidneytumormalignantrcc.html; Accessed 11 March 2024.
  3. Tabatabai ZL, Staerkel GA. Distinguishing primary and metastatic conventional renal cell carcinoma from other malignant neoplasms in fine-needle aspiration biopsy specimens. Arch Pathol Lab Med. 2005 Aug;129(8):1017-21. doi: 10.5858/2005-129-1017-DPAMCR. PMID: 16048391.
  4. Pathology Outlines. Section on Clear Cell RCC. https://www.pathologyoutlines.com/topic/kidneytumormalignantrccclear.html; Accessed 11 March 2024.
  5. Manucha V, Sessums MT, Lewin J, Akhtar I. Cyto-histological correlation of Xp11.2 translocation/TFE3 gene fusion associated renal cell carcinoma: Report of a case with review of literature. Diagn Cytopathol. 2018 Mar;46(3):267-270. doi: 10.1002/dc.23839. Epub 2017 Oct 12. PMID: 29024535.
  6. Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. Am J Surg Pathol. 2013; 37: 1469–1489.
  7. Sharain RF, Gown AM, Greipp PT, Folpe AL. Immunohistochemistry for TFE3 lacks specificity and sensitivity in the diagnosis of TFE3-rearranged neoplasms: a comparative, 2-laboratory study. Hum Pathol. 2019 May;87:65-74. doi: 10.1016/j.humpath.2019.02.008. Epub 2019 Mar 6. PMID: 30851332.
  8. Anna Caliò, Matteo Brunelli, Diego Segala, Serena Pedron, Andrea Remo, Serena Ammendola, Enrico Munari, Francesco Pierconti, Alessandra Mosca, Enrico Bollito, Angelo Sidoni, Simona Fisogni, Cosimo Sacco, Luisa Canu, Steno Sentinelli, Anna Paola Fraccon, Michelangelo Fiorentino, Cathryn Scott, Michele Milella, Camillo Porta, Pedram Argani, Guido Martignoni, Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets, Pathology, Volume 52, Issue 3, 2020,Pages 297-309,ISSN 0031-3025, https://doi.org/10.1016/j.pathol.2019.11.006 (https:www.sciencedirect.com/science/article/pii/S0031302520304566)
  9. Choueiri TK, Lim ZD, Hirsch MS, Tamboli P, Jonasch E, McDermott DF, Dal Cin P, Corn P, Vaishampayan U, Heng DY, Tannir NM. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer. 2010 Nov 15;116(22):5219-25. doi: 10.1002/cncr.25512. PMID: 20665500; PMCID: PMC4667556.
  10. Rudin, C.M., Brambilla, E., Faivre-Finn, C. et al. Small-cell lung cancer. Nat Rev Dis Primers 7, 3 (2021). https://doi.org/10.1038/s41572-020-00235-0
  11. Mariana Nacht, Tatiana Dracheva, Yuhong Gao, Takeshi Fujii, Yidong Chen, Audrey Player, Viatcheslav Akmaev, Brian Cook, Michael Dufault, Mindy Zhang, Wen Zhang, MingZhou Guo, John Curran, Sean Han, David Sidransky, Kenneth Buetow, Stephen L. Madden, and Jin Jen. Molecular characteristics of non-small cell lung cancer December 18, 2001 98 (26) 15203-15208 https://doi.org/10.1073/pnas.261414598
  12. Herold, C. J., A. A. Bankier, and D. Fleischmann. "Lung metastases." European radiology 6 (1996): 596-606.
  13. Quintás-Cardama, Alfonso, and Jorge Cortes. "Molecular biology of bcr-abl1–positive chronic myeloid leukemia." Blood, The Journal of the American Society of Hematology 113.8 (2009): 1619-1630.
  14. Arthur, Diane C., et al. "Translocation 4; 11 in acute lymphoblastic leukemia: Clinical characteristics and prognostic significance." Blood 59.1 (1982): 96-99.
  15. Cuneo, Antonio. "Burkitt’s lymphoma." Atlas of Genetics and Cytogenetics in Oncology and Hematology. Genetic University Hospital, 2001. 281-284.
  16. Sullivan, Kathleen E. "Chromosome 22q11. 2 deletion syndrome and DiGeorge syndrome." Immunological Reviews 287.1 (2019): 186-201.